Biological Products, (No Diagnostic Substances)·OXFORDSHIRE, X0
Financials
9 shown
Type
Period
Ended
Filed
10-K
FY 2025
12/31/25
2/25/26
→
10-Q
Q3 2025
9/30/25
11/6/25
→
10-Q
Q2 2025
6/30/25
8/7/25
→
10-Q
Q1 2025
3/31/25
5/7/25
→
10-K
FY 2024
12/31/24
2/26/25
→
10-Q
Q3 2024
9/30/24
11/6/24
→
↓
Earnings Releases (8-K)
13 shown
Filed
Period
2/25/26
Q1 FY2026
→
1/9/26
Q4 FY2026
→
11/6/25
Q4 FY2025
→
8/7/25
Q3 FY2025
→
5/7/25
Q2 FY2025
→
2/26/25
Q1 FY2025
→
↓
News (8-K)
16 shown
Filed
Type
Description
1/30/26
Exec Change
Departure or Appointment of Directors or Certain Officers
→
11/28/25
Exec Change
Departure or Appointment of Directors or Certain Officers
→
5/15/25
Vote
Submission of Matters to a Vote of Security Holders
→
3/17/25
Other
Other Events
→
3/10/25
Reg FD
Regulation FD Disclosure
→
1/2/25
Exec Change
Departure or Appointment of Directors or Certain Officers
→
↓
Prospectuses & Registrations
22 shown
Filed
Form
Description
5/7/25
S-8
S-8
→
4/4/25
ARS
ARS
→
3/17/25
424B7
427B7
→
3/17/25
POSASR
POSASR
→
4/12/24
ARS
ARS
→
4/5/24
424B7
424B7
→
↓
Filing History(255 filings)
TypeDateAccessionPeriodSize
144
Mar 11, 2026
0001974494-26-000121
—
5.0 KB
SCHEDULE 13G/A
Mar 6, 2026
0001897612-26-000309
—
7.5 KB
8-K
Feb 25, 2026
0001140361-26-0067218-K
Feb 25, 2026
462.2 KB
10-K
Feb 25, 2026
0001671927-26-00000510-K
Dec 31, 2025
11.2 MB
4
Feb 19, 2026
0001969524-26-000002
Feb 17, 2026
8.3 KB
4
Feb 19, 2026
0001730038-26-000002
Feb 17, 2026
14.3 KB
4
Feb 19, 2026
0001779466-26-000002
Feb 17, 2026
14.2 KB
4
Feb 19, 2026
0001969525-26-000002
Feb 17, 2026
9.6 KB
4
Feb 19, 2026
0001955244-26-000002
Feb 17, 2026
9.6 KB
144
Feb 18, 2026
0001974494-26-000058
—
8.3 KB
144
Feb 18, 2026
0001974494-26-000056
—
4.4 KB
144
Feb 18, 2026
0001974494-26-000055
—
4.4 KB
SCHEDULE 13G/A
Feb 17, 2026
0001897612-26-000284
—
7.5 KB
8-K
Jan 30, 2026
0001140361-26-0028948-K
Jan 27, 2026
199.0 KB
8-K
Jan 9, 2026
0001140361-26-0007808-K
Jan 9, 2026
9.1 MB
4
Dec 8, 2025
0001955244-25-000015
Dec 4, 2025
14.6 KB
4
Dec 1, 2025
0001955244-25-000013
Nov 26, 2025
14.6 KB
8-K
Nov 28, 2025
0001140361-25-0436008-K
Nov 26, 2025
197.4 KB
4
Nov 26, 2025
0001955244-25-000011
Nov 24, 2025
14.1 KB
144
Nov 24, 2025
0001968582-25-001112
—
8.0 KB
SCHEDULE 13G
Nov 14, 2025
0001104659-25-112824
—
9.1 KB
8-K
Nov 6, 2025
0001140361-25-0406648-K
Nov 6, 2025
462.0 KB
10-Q
Nov 6, 2025
0001671927-25-00001810-Q
Sep 30, 2025
5.2 MB
SCHEDULE 13G
Oct 24, 2025
0001214659-25-015287
—
26.2 KB
SCHEDULE 13G/A
Oct 3, 2025
0000059478-25-000243
—
8.0 KB
25 filings shown
Proxies
4 shown
Filed
Form
Description
4/4/25
DEF 14A
DEF 14A
→
3/24/25
PRE 14A
PRE 14A
→
4/12/24
DEF 14A
DEF 14A
→
4/2/24
PRE 14A
PRE 14A
→
Ownership
40 shown
Filed
Form
Description
2/19/26
4
4
→
2/19/26
4
4
→
2/19/26
4
4
→
2/19/26
4
4
→
2/19/26
4
4
→
12/8/25
4
4
→
↓
Other Filings
40 shown
Filed
Form
Description
3/11/26
144
144
→
3/6/26
SCHEDULE 13G/A
SCHEDULE 13G/A
→
2/18/26
144
144
→
2/18/26
144
144
→
2/18/26
144
144
→
2/17/26
SCHEDULE 13G/A
SCHEDULE 13G/A
→
↓
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.